This hypothesis proposes that targeting CD38, the primary NAD+-consuming enzyme, represents a more direct therapeutic approach to metabolic dysfunction than NAD+ precursor supplementation. CD38 expression increases dramatically with aging and inflammation, creating a futile cycle where enhanced NAD+ consumption outpaces biosynthetic capacity. Rather than attempting to replenish NAD+ pools through precursor loading, selective CD38 inhibition would preserve endogenous NAD+ levels by blocking its e
This hypothesis proposes that NAD+ precursor supplementation can restore neuronal ketone body utilization by activating SIRT1-mediated transcriptional upregulation of MCT1 (monocarboxylate transporter 1). In neurodegenerative conditions, chronic PARP1 activation depletes cellular NAD+ pools, leading to reduced SIRT1 activity and subsequent downregulation of MCT1 expression. This creates a metabolic bottleneck where neurons cannot efficiently import ketone bodies as an alternative fuel source, ex
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
SenescenceUnspecified Mechanismmetabolomics
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
8/11
dimensions won
CD38 Inhibition to Prevent NAD+ Depletio
8/11
dimensions won
NAD+-Dependent Transcriptional Upregulat
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.65
0.65
Evidence
0.26
0.26
Novelty
0.00
0.00
Feasibility
0.00
0.00
Impact
0.00
0.00
Druggability
0.80
0.80
Safety
0.50
0.50
Competition
0.60
0.60
Data
0.65
0.65
Reproducible
0.55
0.55
KG Connect
0.50
0.50
Score Breakdown
Dimension
CD38 Inhibition to Prevent NAD
NAD+-Dependent Transcriptional
Mechanistic
0.650
0.650
Evidence
0.258
0.258
Novelty
0.000
0.000
Feasibility
0.000
0.000
Impact
0.000
0.000
Druggability
0.800
0.800
Safety
0.500
0.500
Competition
0.600
0.600
Data
0.650
0.650
Reproducible
0.550
0.550
KG Connect
0.500
0.500
Evidence
CD38 Inhibition to Prevent NAD+ Depletion and Restore Cellul
No evidence citations yet
NAD+-Dependent Transcriptional Upregulation of MCT1 to Resto
No evidence citations yet
Debate Excerpts
CD38 Inhibition to Prevent NAD+ Depletion and Rest
4 rounds · quality: 0.50
Theorist
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...
NAD+-Dependent Transcriptional Upregulation of MCT
4 rounds · quality: 0.50
Theorist
# Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration
---
## Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation
**Title:** MCT1 transporter upregu...
Skeptic
# Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration
I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanati...
Domain Expert
# Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration
## Executive Summary
All seven hypotheses face significant translational barriers. The metabolomics field provides genuine...